ArQule would receive $75 million in up-front cash under two deals with Japan's Daiichi Sankyo Co. Ltd. - one to develop an anticancer compound and the other to discover a new generation of kinase inhibitors for cancer. (BioWorld Today)
Onyx Pharmaceuticals Inc. took another step toward building its pipeline by licensing an anticancer compound from London-based BTG plc, in a deal that could bring in as much as $320 million for the UK company. (BioWorld Today)
Genzyme Corp. and Osiris Therapeutics Inc. have agreed to develop and commercialize two stem cell products, in a deal that would provide Osiris with up to $1.25 billion in potential milestone payments and $130 million up front. (BioWorld Today)
